Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Nursing Education Scholarship|February 13, 2019
Structure and Content of a New Entrance Exam to Select Undergraduate Nursing StudentsElina Haavisto, Maija Hupli, Nina Hahtela, et al.
The Journal of Gene Medicine|April 27, 2011
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patientsMari Raki, Merja Sarkioja, Sophie Escutenaire, et al.
Human Gene Therapy|January 24, 2019
Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy ConstructsCamilla Heiniö, Suvi Sorsa, Mikko Siurala, et al.
Molecular Pharmaceutics|October 23, 2010
Safety of glucocorticoids in cancer patients treated with oncolytic adenovirusesMaria Rajecki, Mari Raki, Sophie Escutenaire, et al.
Annals of Medicine|January 26, 2011
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartmentsSophie Escutenaire, Vincenzo Cerullo, Iulia Diaconu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumorsPetri Nokisalmi, Sari Pesonen, Sophie Escutenaire, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2011
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirusVincenzo Cerullo, Iulia Diaconu, Lotta Kangasniemi, et al.
International Journal of Cancer|June 2, 2011
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumorsSari Pesonen, Iulia Diaconu, Vincenzo Cerullo, et al.
Cancer Research|February 11, 2012
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patientsSari Pesonen, Iulia Diaconu, Lotta Kangasniemi, et al.
Oncoimmunology|May 6, 2015
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarizationTuuli Ranki, Timo Joensuu, Elke Jäger, et al.
Pageof 9